Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic?

Eur Heart J. 2020 Jun 14;41(23):2140-2144. doi: 10.1093/eurheartj/ehaa506.
No abstract available

MeSH terms

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Anticoagulants / therapeutic use
  • Antimalarials / therapeutic use
  • Antiviral Agents / therapeutic use
  • Azithromycin / therapeutic use
  • Betacoronavirus
  • Biomedical Research
  • COVID-19
  • COVID-19 Drug Treatment
  • COVID-19 Serotherapy
  • COVID-19 Testing
  • Clinical Laboratory Techniques / standards
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / therapy*
  • Data Accuracy
  • Device Approval*
  • Diagnostic Test Approval*
  • Drug Approval*
  • Drug and Narcotic Control
  • European Union*
  • Glucocorticoids / therapeutic use
  • Heparin / therapeutic use
  • Humans
  • Immunization, Passive / standards
  • Medical Device Legislation
  • Pandemics
  • Personal Protective Equipment / standards
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / therapy*
  • SARS-CoV-2
  • Ventilators, Mechanical / standards

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Antimalarials
  • Antiviral Agents
  • Glucocorticoids
  • Azithromycin
  • Heparin
  • tocilizumab